Obecabtagene autoleucel (obe-cel; Aucatzyl) led to a complete response (CR)/CR with incomplete hematologic recovery (CRi) rate in more than 70% of all age-stratified patient subgroups with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback